{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:23:29Z","timestamp":1747200209522,"version":"3.40.5"},"reference-count":35,"publisher":"Media Sphere Publishing House","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rus. Ann. Ophthal."],"published-print":{"date-parts":[[2023,12,29]]},"abstract":"<jats:p>Intravitreal injections (IVI) of vascular endothelial growth factor (VEGF) inhibitors are actively used in the treatment of various ophthalmic pathologies. In addition to the pronounced therapeutic effect of anti-VEGF drugs described in the literature, a number of data on adverse effects associated with the use of IVI, including from the lens, have now been accumulated. Prevention of possible side effects of this type of treatment requires further investigation. Purpose. The study evaluates the changes in spectrofluorometric parameters of the lens after intravitreal injections of brolucizumab in eyes with native lens. Material and methods. The study included 13 people with neovascular age-related macular degeneration (AMD) who received IVI of brolucizumab. All patients were over 40 years old; changes in central retinal thickness in the macular area exceeded 300 \u03bcm according to optical coherence tomography. Spectrofluorimetric indicators of the lens were studied before and after injections of the drug in both eyes. The spectra were analyzed in the wavelength range 412\u2014698 nm to record the changes in the content of non-tryptophan fluorophore molecules in the lens. Results. Spectrofluorimetry revealed metabolic changes in the native lens after intravitreal injections of the drug brolucizumab. No such changes were observed in the lens of the eyes not injected with the drug (the \u00abControl\u00bb group). The proposed investigation technique involves prospective assessment of the safety of various molecules injected intravitreally in terms of cataract development at various times after the injection. Conclusion. Spectrofluorimetry can be used for identifying initial metabolic changes in the lens. It is a promising method for assessing the molecules used in intravitreal injections in terms of their safety for the native lens, as well as for development of detailed instructions for clinically substantiated use of drugs with adverse effects in the form of cataract induction. According to spectrofluorimetry, IVI of the drug brolucizumab affects metabolic changes in the lens.<\/jats:p>","DOI":"10.17116\/oftalma202313906141","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T12:40:48Z","timestamp":1705581648000},"page":"41","source":"Crossref","is-referenced-by-count":0,"title":["Spectrofluorimetric changes in the lens after intravitreal injections of brolucizumab"],"prefix":"10.17116","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-1768","authenticated-orcid":false,"given":"V.V.","family":"Gar\u2019kavenko","sequence":"first","affiliation":[{"name":"Krasnoyarsk Regional Ophthalmological Clinical Hospital named after Professor P.G. Makarov","place":["Krasnoyarsk, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4441-9025","authenticated-orcid":false,"given":"V.V.","family":"Salmin","sequence":"additional","affiliation":[{"name":"National Research Nuclear University \u00abMEPhI\u00bb (Moscow Engineering Physics Institute)","place":["Moscow, Russia"]},{"name":"Moscow Institute of Physics and Technology (National Research University)","place":["Dolgoprudniy, Russia"]},{"name":"Moscow State Technical University named after N.E. Bauman (National Research University)","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8927-3907","authenticated-orcid":false,"given":"P.M.","family":"Balashova","sequence":"additional","affiliation":[{"name":"Krasnoyarsk Regional Ophthalmological Clinical Hospital named after Professor P.G. Makarov","place":["Krasnoyarsk, Russia"]},{"name":"Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky","place":["Krasnoyarsk, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8571-8349","authenticated-orcid":false,"given":"V.S.","family":"Gaydelis","sequence":"additional","affiliation":[{"name":"Krasnoyarsk Regional Ophthalmological Clinical Hospital named after Professor P.G. Makarov","place":["Krasnoyarsk, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0509-423X","authenticated-orcid":false,"given":"D.S.","family":"Kokozova","sequence":"additional","affiliation":[{"name":"Krasnoyarsk Regional Ophthalmological Clinical Hospital named after Professor P.G. Makarov","place":["Krasnoyarsk, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/oftalma202313906141-1","unstructured":"Steinmetz JD. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Global Health. 2021;9(2):e144-e160"},{"key":"key-10.17116\/oftalma202313906141-2","unstructured":"Williams GA. IVT injections: health policy implications. Rev Ophthalmol. 2014;21:62-64"},{"key":"key-10.17116\/oftalma202313906141-3","unstructured":"Boyko EV, Sosnovsky SV, Berezin RD, Kacherovich PA, Tavtilova DA. Intravitreal injections: theory and practice. Ophthalmology Reports = Oftal\u2019mologicheskie vedomosti. 2010;3(2):28-35. (In Russ.)"},{"key":"key-10.17116\/oftalma202313906141-4","doi-asserted-by":"crossref","unstructured":"Enoch J, Ghulakhszian A, Sekhon M, Crabb DP, Taylor DJ, Dinah C. Towards a Therapy for Geographic Atrophy: A Patient\u2019s Experience. Patient Prefer Adher. 2023;17:299-310","DOI":"10.2147\/PPA.S386662"},{"key":"key-10.17116\/oftalma202313906141-5","doi-asserted-by":"crossref","unstructured":"Rofagha S. Minimizing risks to patients by improving presentation of clinical trial results in geographic atrophy trials. Ophthalmol Retina. 2022;6(5): 337-338","DOI":"10.1016\/j.oret.2021.12.018"},{"key":"key-10.17116\/oftalma202313906141-6","doi-asserted-by":"crossref","unstructured":"Khan H, Aziz AA, Sulahria H, Khan H, Ahmed A, Choudhry N, Narayanan R, Danzig C, Khanani AM Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration. Clin Ophthalmol. 2023;17:321-327","DOI":"10.2147\/OPTH.S367089"},{"key":"key-10.17116\/oftalma202313906141-7","doi-asserted-by":"publisher","DOI":"10.22608\/APO.201837"},{"key":"key-10.17116\/oftalma202313906141-8","doi-asserted-by":"publisher","DOI":"10.18821\/1993-1859-2016-11-4-212-220"},{"key":"key-10.17116\/oftalma202313906141-9","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjopt.2015.01.007"},{"key":"key-10.17116\/oftalma202313906141-10","doi-asserted-by":"crossref","unstructured":"Fung AE, Rosenfeld PJ, Reichel E. The International Bevacizumab safety Surrey: using the Internet to assess drug safety Worldwide. Br J Ophthalmol. 2006;90(11):1344-1349","DOI":"10.1136\/bjo.2006.099598"},{"key":"key-10.17116\/oftalma202313906141-11","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0461-z"},{"key":"key-10.17116\/oftalma202313906141-12","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200510000-00022"},{"key":"key-10.17116\/oftalma202313906141-13","unstructured":"Stone TW, ed. ASRS 2018 Preferences and Trends Member- ship Survey. Chicago, IL. American Society of Retina Specialists; 2018. Accessed: 13.05.21.  https:\/\/www.asrs.org\/content\/documents\/_2018-pat-survey-results-for-website.pdf"},{"key":"key-10.17116\/oftalma202313906141-14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.1815"},{"key":"key-10.17116\/oftalma202313906141-15","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-019-0184-9"},{"key":"key-10.17116\/oftalma202313906141-16","doi-asserted-by":"publisher","DOI":"10.32364\/2311-7729-2021-21-4-227-234"},{"key":"key-10.17116\/oftalma202313906141-17","doi-asserted-by":"crossref","unstructured":"Af Segerstad PH. Risk model for intraoperative complication during cataract surgery based on data from 900 000 eyes: previous intravitreal injection is a risk factor. Brit J Ophthalmol. 2022;106(10):1373-1379","DOI":"10.1136\/bjophthalmol-2020-318645"},{"key":"key-10.17116\/oftalma202313906141-18","doi-asserted-by":"publisher","DOI":"10.1159\/000528657"},{"key":"key-10.17116\/oftalma202313906141-19","doi-asserted-by":"crossref","unstructured":"Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24(5):676-698","DOI":"10.1097\/00006982-200410000-00002"},{"key":"key-10.17116\/oftalma202313906141-20","doi-asserted-by":"crossref","unstructured":"Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006;58:1136-1163","DOI":"10.1016\/j.addr.2006.07.024"},{"key":"key-10.17116\/oftalma202313906141-21","doi-asserted-by":"publisher","DOI":"10.21516\/2072-0076-2022-15-2-37-41"},{"key":"key-10.17116\/oftalma202313906141-22","doi-asserted-by":"publisher","DOI":"10.25881\/20728255-2022-17-4-S1-22"},{"key":"key-10.17116\/oftalma202313906141-23","doi-asserted-by":"crossref","unstructured":"Siik S. Lens autofluorescence and light scatter in relation to the lens opacities classification system, LOCS III. Acta Ophthalmol Scand. 1999;77(5): 509-514","DOI":"10.1034\/j.1600-0420.1999.770504.x"},{"key":"key-10.17116\/oftalma202313906141-24","doi-asserted-by":"crossref","unstructured":"Holl\u00f3 CT, Mih\u00e1ltz K, Kurucz M, Csorba A, Kr\u00e1nitz K, Kov\u00e1cs I, Nagy ZZ, Erdei G. Objective quantification and spatial mapping of cataract with a Shack-Hartmann wavefront sensor. Sci Rep. 2020;10(1):12585","DOI":"10.1038\/s41598-020-69321-3"},{"key":"key-10.17116\/oftalma202313906141-25","doi-asserted-by":"crossref","unstructured":"De Castro A, Benito A, Manzanera S, Mompe\u00e1n J, Ca\u00f1izares B, Mart\u00ednez D, Mar\u00edn JM, Grulkowski I, Artal P. Three-dimensional cataract crystalline lens imaging with swept-source optical coherence tomography. Invest Ophthalmol Vis Sci. 2018;59(2):897-903","DOI":"10.1167\/iovs.17-23596"},{"key":"key-10.17116\/oftalma202313906141-26","doi-asserted-by":"publisher","DOI":"10.18008\/1816-5095-2022-4-740-745"},{"key":"key-10.17116\/oftalma202313906141-27","doi-asserted-by":"crossref","unstructured":"Bullard B. Pyridine nucleotides in the lens of different species. Exper Eye Res. 1965;4(2):108-111","DOI":"10.1016\/S0014-4835(65)80020-3"},{"key":"key-10.17116\/oftalma202313906141-28","doi-asserted-by":"crossref","unstructured":"Stewart RC. Augusteyn, Pyridine nucleotides in normal and cataractous human lenses. Expe Eye Res. 1984;39(3):307-315","DOI":"10.1016\/0014-4835(84)90018-6"},{"key":"key-10.17116\/oftalma202313906141-29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29607-8"},{"key":"key-10.17116\/oftalma202313906141-30","doi-asserted-by":"publisher","DOI":"10.1070\/RC2008v077n09ABEH003880"},{"key":"key-10.17116\/oftalma202313906141-31","doi-asserted-by":"publisher","DOI":"10.1007\/s10812-017-0464-9"},{"key":"key-10.17116\/oftalma202313906141-32","doi-asserted-by":"crossref","unstructured":"Vladimirova ES, Salmin VV, Salmina AB, Oskirko SA, Lazarenko VI. Fluorescence diagnosis of the status of the human lens in vivo. J Appl Spectroscopy. 2012;79(1):126-130","DOI":"10.1007\/s10812-012-9573-7"},{"key":"key-10.17116\/oftalma202313906141-33","doi-asserted-by":"publisher","DOI":"10.21516\/2072-0076-2017-10-4-16-19"},{"key":"key-10.17116\/oftalma202313906141-34","doi-asserted-by":"publisher","DOI":"10.21516\/2072-0076-2020-13-2-41-44"},{"key":"key-10.17116\/oftalma202313906141-35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.1999.tb08289.x"}],"container-title":["Russian Annals of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T13:48:45Z","timestamp":1745502525000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/vestnik-oftalmologii\/2023\/6\/10042465X2023061041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12,29]]}},"alternative-id":["10.17116\/oftalma202313906141"],"URL":"https:\/\/doi.org\/10.17116\/oftalma202313906141","relation":{},"ISSN":["0042-465X"],"issn-type":[{"type":"print","value":"0042-465X"}],"subject":[],"published":{"date-parts":[[2023,12,29]]}}}